Lilly direct-selling Zepbound at $499/mo — compare with 11 other programs

Orforglipron vs Rybelsus

Editorial comparison of Orforglipron (orforglipron) and Rybelsus (semaglutide (oral)). Same drug class context, trial-anchored data, no marketing claims.

Reviewed by the glpzoom Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of June 2026; updated when guidance or availability changes.

Side-by-side

DimensionOrforglipronRybelsus
Generic nameorforglipronsemaglutide (oral)
ManufacturerEli LillyNovo Nordisk
FDA approved20262019
MechanismSame target as injectable GLP-1s — the GLP-1 receptor — but a non-peptide small-molecule structure.GLP-1 receptor agonist, identical mechanism to injectable semaglutide.
DosingOnce-daily oral tablet, titrated upward over several weeks to manage GI side effects. No fasting or water-timing restrictions (unlike Rybelsus).Once daily on an empty stomach with ≤4 oz water, 30 minutes before food/drink/other meds. Titrated 3mg → 7mg → 14mg.
Cost$149/month via LillyDirect cash-pay at launch — meaningfully below branded injectable list prices.List ~$900-1,000/month. Diabetes coverage generally better than weight-loss coverage. NovoCare self-pay options available for eligible patients.
Pivotal trial result~14-15% mean body-weight reduction in Phase 3 (highest dose)

Full Orforglipron review →

First once-daily oral non-peptide GLP-1. Brand-only, launching via LillyDirect at $149/month. No injection, no compounded versions.

Full Rybelsus review →

Oral semaglutide tablet for type 2 diabetes. Same molecule as Ozempic/Wegovy in pill form, with strict fasting-and-water dosing rules.

Frequently asked

Is Orforglipron or Rybelsus more effective?+

In their pivotal trials, Orforglipron reported ~14-15% mean body-weight reduction in Phase 3 (highest dose), while Rybelsus reported no headline result on file. Head-to-head results vary by patient profile, dose tolerated, and adherence — these trial numbers describe averages, not what every individual experiences.

How do Orforglipron and Rybelsus compare on cost?+

Orforglipron: $149/month via LillyDirect cash-pay at launch — meaningfully below branded injectable list prices. Insurance coverage will expand through 2026-2027 as formularies add it. Rybelsus: List ~$900-1,000/month. Diabetes coverage generally better than weight-loss coverage. NovoCare self-pay options available for eligible patients. Real out-of-pocket depends on insurance formulary tier, manufacturer savings programs, and whether a direct-pay channel is available.

Can I switch from Orforglipron to Rybelsus?+

Switching between brand-name treatments in the same drug class is common, but the conversion is not always 1:1. Discuss the switch with your prescriber — they'll usually re-titrate dosing rather than substitute equivalent strengths directly.

Are Orforglipron and Rybelsus the same drug?+

No. Orforglipron (orforglipron) and Rybelsus (semaglutide (oral)) are distinct medications from Eli Lilly and Novo Nordisk respectively. They may share a drug class or mechanism but differ in active ingredient, dosing, and approved use.

We may earn a commission when you click links to partners. Affiliate disclosure.